Compound 4h MARK4 inhibitor (RGNCY-0129)
Per 10 mg
Compound 4h is a novel selective MARK4 inhibitor with binding verified by molecular docking and flourescence biding assays. MARK4 is a therapeutic target for cancer drug development due to its involvement in microtubule dynamics, cell cycle regulation and cancer progression. Compound 4h exhibited apoptotic, antiproliferative and antioxidant activity in cell-based assays. 4h has a K value of 3.6 x 103 M-1 for human serum albumin demonstrating its remarkable transportation and delivery properties to the target site through the blood.
Systematic Name: (Z)-(5-nitro-1H-imidazol-1-yl)(2-(trifluoromethyl)phenyl)methanone oxime
Mol Wt: 300.20
Peerzada MN et al. Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy. ACS Omega. 2020 Sep 1;5(36):22759-22771.
There are no uploaded files